IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

8.01 -3.03% (-0.25)

Over 6M: +111.3%

2026-08-28
Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

4 6 8
Mar Apr May Jun Jul Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Revenue: 67.5M Q3 '25 — Free Cash Flow: -89.5M Q3 '25 — Net Income: -91.3M Q4 '25 — Revenue: 86.8M Q4 '25 — Free Cash Flow: -61.9M Q4 '25 — Net Income: -71.9M Q1 '26 — Revenue: 71.4M Q1 '26 — Free Cash Flow: -78.7M Q1 '26 — Net Income: -79M Q2 '26 — Revenue: 99.3M Q2 '26 — Free Cash Flow: -66.3M Q2 '26 — Net Income: -47.3M -80M -40M 0 40M 80M 120M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

1.4
SBC / sales 14.4%
OE margin -105.6%
Oper. margin -92.7%
ROIC -54.2%
Accruals -2.8%
Gross margin 48.4%
EBITDA margin -88.6%
FCF margin -91.2%
OCF margin -81.3%
Profit margin -89.1%
ROA -31.6%
ROCE -37.3%
ROE -39.3%
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

2 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.7
ND/EBITDA —
Cash runway 1.0 yr
Cash / Debt 297.7×
Debt / Eq 0.0014×
Debt payback 0.0 yr
Quick ratio 3.8×
F-score 2.2 pts
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

5.2
Sales/sh Y/Y +9.1%
Sales Q/Q +65.7%
Shares change +23.3%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —

2 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.